NCT03795779View on ClinicalTrials.gov

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative NeoplasmChronic Myeloid Leukemia
Interventions
BIOLOGICAL

CLL1-CD33 cCAR T cells

CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.

Trial Locations (2)

Unknown

RECRUITING

The General Hospital of Western Theater Command, Chengdu

NOT_YET_RECRUITING

Peking University Shenzhen Hospital, Shenzhen

Sponsors
All Listed Sponsors
collaborator

The General Hospital of Western Theater Command

OTHER

collaborator

iCAR Bio Therapeutics Ltd.

INDUSTRY

collaborator

Peking University Shenzhen Hospital

OTHER

lead

iCell Gene Therapeutics

INDUSTRY